Repeated administration of high-dose depot medroxyprogesterone acetate does not alter SHIVSF162p3 viral kinetics and tenofovir pharmacokinetics when delivered via intravaginal rings.

Autor: Srinivasan, Priya, Zhang, Jining, Dinh, Chuong T., Teller, Ryan S., McNicholl, Janet M., Kiser, Patrick F., Herold, Betsy C., Smith, James M.
Předmět:
Zdroj: Journal of Medical Primatology; Aug2017, Vol. 46 Issue 4, p129-136, 8p
Abstrakt: Background Intravaginal rings ( IVR) for HIV prevention will likely be used by women on depot medroxyprogesterone acetate ( DMPA) hormonal contraception. We used pigtailed macaques to evaluate the effects of DMPA on tenofovir disoproxil fumarate ( TDF) IVR pharmacokinetics and viral shedding. Methods Mucosal tenofovir ( TFV) levels were compared in SHIVSF162p3-negative DMPA-treated (n=4) and normally cycling (n=6) macaques receiving TDF IVRs. Plasma viremia and vaginal shedding were determined in groups of SHIVSF162p3-positive DMPA-treated (n=6) and normally cycling (n=5) macaques. Results Similar median vaginal fluid TFV concentrations were observed in the DMPA-treated and cycling macaques over 4 weeks (1.2×105 and 1.1.×105 ng/ mL, respectively). Median plasma viremia and vaginal shedding AUC of the DMPA-treated (2.73×107 and 8.15×104 copies/ mL, respectively) and cycling macaques (3.98×107 and 1.47×103 copies/ mL, respectively) were statistically similar. Conclusions DMPA does not affect TDF IVR pharmacokinetics or SHIV shedding. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje